Pacira BioSciences, Inc.PCRXNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank57
3Y CAGR-2.8%
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

3Y CAGR
-2.8%/yr
vs +29.7%/yr prior
Acceleration
-32.6pp
Decelerating
Percentile
P57
Within normal range
vs 3Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202525.39%
20249.15%
20235.86%
202227.68%
20213.01%
2020-3.62%
201913.27%
20189.77%
20175.82%
20169.76%